News Releases
View all Historical Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 2, 2018Specific therapeutic use claim in oral mucositis adds to existing composition of matter claims
Princeton, NJ – January 2, 2018 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Dec 21, 2017
Princeton, NJ – December 21, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Nov 30, 20172017 Non-Dilutive Funding Exceeds $8.6 Million
Princeton, NJ – November 30, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Nov 27, 2017
Princeton, NJ – November 27, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Nov 13, 2017
Princeton, NJ – November 13, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Nov 9, 2017
PRINCETON, NJ – November 9, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Nov 6, 20172017 Non-Dilutive Funding Exceeds $8M
PRINCETON, NJ – November 6, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Nov 3, 2017
PRINCETON, NJ – November 3, 2017 – Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Oct 31, 2017
PRINCETON, NJ – October 31, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Oct 24, 2017
PRINCETON, NJ – October 24, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Oct 17, 2017
Princeton, NJ – October 17, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Oct 5, 2017
PRINCETON, NJ – October 5, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Sep 25, 20172017 Non-Dilutive Funding Exceeds $8M
PRINCETON, NJ – September 25, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Sep 20, 20172017 Non-Dilutive Funding Reaches $7.5 Million
PRINCETON, NJ – September 20, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Sep 18, 20172017 Non-Dilutive Funding Climbs to $6 Million
PRINCETON, NJ – September 18, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Sep 11, 2017
PRINCETON, NJ – September 11, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Sep 7, 2017
Princeton, NJ – September 7, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Sep 5, 2017
Princeton, NJ – September 5, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Aug 14, 2017
PRINCETON, NJ – August 14, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Aug 11, 2017
PRINCETON, NJ – August 11, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Jul 27, 2017“DOM–INNATE” study opens patient enrollment
PRINCETON, NJ – July 27, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Jul 6, 2017Dusquetide Technology Platform to be Presented at the 2017 Drug Discovery and Therapy World Congress
PRINCETON, NJ – July 6, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Jun 21, 2017Awarded $2M to Advance Preclinical Efficacy Studies
PRINCETON, NJ – June 21, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Jun 19, 2017
PRINCETON, NJ – June 19, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
May 18, 2017At 12 Months SGX942 Found to be Safe and Well Tolerated with Multiple Potential Ancillary Benefits
PRINCETON, NJ – May 18, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...